Physician
Rajput, Muhammad
Rajput, Muhammad was paid $3.31M by Medicaid between Oct 2019 and Nov 2024, across 58 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 25% of everything it billed.
33Billing provider infoRAJPUT, MUHAMMAD
HOUSTON, TX 77090
HOUSTON, TX 77090
33aNPI1558360248assigned 07/15/2005
33bProvider typePediatrics Physician
28Total paid$3.31M
24GClaims131,076
24DCodes billed58
24AFirst – last monthOct 2019 – Nov 2024
Compared with peers
Next to other Pediatrics Physician providers in Texas
Rank by total paid#142 of 1,136
Median peer was paid$329K
This provider vs. median10×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 1,788 | $42K | |
| 2020 | 15,709 | $326K | |
| 2021 | 35,560 | $759K | |
| 2022 | 33,397 | $907K | |
| 2023 | 28,685 | $834K | |
| 2024incomplete | 15,937 | $440K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 25% | 21,752 | 19,197 | $818K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 11% | 4,347 | 4,184 | $354K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 11% | 4,116 | 3,950 | $352K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 6.8% | 2,937 | 2,765 | $224K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 6.2% | 2,206 | 2,118 | $205K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 5.6% | 6,366 | 6,039 | $185K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 5.4% | 16,143 | 8,321 | $178K |
| S8301 | Infection control supplies, not otherwise specified | 4.7% | 15,483 | 12,867 | $154K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 4.6% | 1,942 | 1,850 | $151K |
| 99429 | 4.1% | 3,988 | 3,839 | $135K | |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 3.3% | 2,083 | 1,995 | $111K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.7% | 1,057 | 1,021 | $55K |
46 more codes
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.6% | 2,147 | $53K |
| 87634 | 1.6% | 947 | $52K | |
| 99050 | 1.5% | 3,418 | $48K | |
| 99381 | 1.3% | 627 | $45K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 1.2% | 4,678 | $38K |
| 99383 | <1% | 354 | $33K | |
| 90461 | <1% | 3,087 | $22K | |
| 97803 | <1% | 5,845 | $21K | |
| 99382 | <1% | 187 | $17K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,206 | $16K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 783 | $11K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 677 | $9K |
| 99384 | <1% | 79 | $8K | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 381 | $4K |
| T1013 | Sign language or oral interpretive services, per 15 minutes | <1% | 457 | $2K |
| 96160 | <1% | 918 | $2K | |
| 96161 | <1% | 627 | $1K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 24 | $921.26 |
| 87807 | <1% | 69 | $738.65 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 18 | $557.57 |
| A7016 | Dome and mouthpiece, used with small volume ultrasonic nebulizer | <1% | 114 | $493.58 |
| 69210 | <1% | 13 | $449.50 | |
| 97802 | <1% | 71 | $308.88 | |
| A7003 | Administration set, with small volume nonfiltered pneumatic nebulizer, disposable | <1% | 115 | $228.11 |
| 99056 | <1% | 90 | $188.65 | |
| 90686 | <1% | 2,280 | $39.20 | |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | <1% | 5,718 | $4.06 |
| 90697 | <1% | 1,383 | $1.47 | |
| 90677 | <1% | 483 | $1.36 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 521 | $0.63 |
| 90619 | <1% | 264 | $0.22 | |
| 90651 | <1% | 576 | $0.15 | |
| 90681 | <1% | 277 | $0.07 | |
| 90715 | <1% | 528 | $0.04 | |
| 90660 | <1% | 393 | $0.01 | |
| 90696 | <1% | 468 | $0.01 | |
| 90620 | <1% | 180 | $0.01 | |
| J7612 | Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 0.5 mg | 0% | 509 | $0.00 |
| 90680 | 0% | 845 | $0.00 | |
| 90723 | 0% | 547 | $0.00 | |
| 90710 | 0% | 1,362 | $0.00 | |
| 90670 | 0% | 1,967 | $0.00 | |
| 90648 | 0% | 992 | $0.00 | |
| 90700 | 0% | 344 | $0.00 | |
| 90633 | 0% | 1,488 | $0.00 | |
| 90734 | 0% | 599 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.